ClinicalTrials.gov
public full text
Public Domain
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
The investigators hypothesize that Cana may be able to improve number and function of CD34+ endothelial progenitor cells. The investigators also propose that this expected cardiovascular benefit is independent of HbA1C reduction. Subjects will begin taking 100 mg of Cana or placebo after initial 4 weeks. Subjects will be withdrawn from the study if the medication or placebo is not tolerated.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes#1195110
- Evaluation of endothelial dysfunction in women with prolactinoma#1136603
- Epidemiology of Diabetes Interventions and Complications (EDIC)#813171
- Time-In-Range Based Risk Stratification of Type 2 Diabetes Microvascular Complications#1094513
- Effects of Canagliflozin on Intravascular Volume and Hemodynamics#887530
Record · ID 1262201
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive